P169 Treatment effects of ixekizumab and adalimumab at the individual digit level with nail and distal interphalangeal joint involvement in patients with psoriatic arthritis

Abstract Background/Aims Psoriatic nail disease is intimately linked to adjacent distal interphalangeal joint (DIP) disease, and it important ascertain whether DIP-nail complex behaves differently under different biological therapies. The aim of this analysis assess the effect ixekizumab (IXE) adalimumab (ADA) at individual digit level using Nail Psoriasis Severity Index (NAPSI) NAPSI resolution in patients with psoriatic arthritis (PsA) concomitant involvement. Methods This post hoc included from SPIRIT-H2H (NCT03151551) treated either IXE or ADA who had baseline (NAPSI total score >0) DIP involvement, tenderness swelling, for each hand. was assessed scoring system, a measure bed matrix involvement combined maximum 80. Proportions having >0 were evaluated baseline, week 24 52; post-baseline assessments compared between treatment Fisher’s exact test. Results Of 566 intent-to-treat population of, 354 (IXE, N = 186; ADA, 168) least 1 10 digits simultaneously baseline. At 24, proportion lower among received versus across all significantly 9 out (p < 0.05; Table) additional improvements 52. On average, 10% difference observed, favouring IXE. Similarly, numerically greater observed regardless bed, matrix, assessed. Conclusion These data demonstrate that PsA there significant advantage over resolving as measured by NAPSI. Disclosure D. McGonagle: Consultancies; Eli Lilly Company, AbbVie. Member speakers’ bureau; Company. Grants/research support; Other; BSR attendance support A. Kavanaugh: AbbVie, UCB, Janssen, Novartis, Pfizer. I. McInnes: Amgen, BMS, Causeway Therapeutics, Cabaletta, Gilead, Pfizer, Sanofi Regeneron, UCB. UCB Pharma. University Glasgow, Vice Principal & Head College, NHS Greater Glasgow Clyde, Non exec board member, Evelo, Board Directors, Exec director, Versus arthritis, Trustee. L. Kristensen: Biogen, MSD, Janssen. study grant Novo Nordisk A/S, institutional Oak Foundation, Cambridge Weight Plan, delivery dietary supplements. J.F. Merola: Bristol-Myers Squibb, Dermavant, Sanofi, Sun Pharma, Leo B.E. Strober: Alumis, Almirall, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Bristol-Myers-Squibb, Connect Biopharma, EPI Health, Evelo Biosciences, Leo, Maruho, Meiji Seika Mindera Sanofi-Genzyme, Union Ventyxbio, vTv Therapeutics. Shareholder/stock ownership; Health. Honoraria; Editor-in-Chief (honorarium): Journal Arthritis. Incyte, Sanofi-Genzyme. Investigator: CorEvitas Registry, Dermira, Cara, Novertis. J.R. Lisse: Corporate appointments; J. Pustizzi: C. Sapin: R. Bolce: Ritchlin: